Incyte – pharmaceutical daily

March 23, 2021 Off

Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy

Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of patients with unresectable biliary tract cancer.

May 5, 2020 Off

Incyte posts Q1 2020 product, royalty revenues of $569M

By BusinessWire

Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended March 31, 2020; Jakafi® (ruxolitinib) revenues of $459 million in Q1 2020 (+22% vs Q1 2019).

April 28, 2020 Off

Incyte prepares oncology, dermatology products

By Dino Mustafić

Incyte last week named new Canada Biosciencess head, announcing establishing key development and commercialization capabilities in preparation for potential launches of multiple products in the near future.

April 24, 2020 Off

– Incyte names new general manager for Biosciences Canada

By BusinessWire

MONTREAL–(BUSINESS WIRE)–$INCY—Incyte (Nasdaq:INCY) has appointed Christine Lennon as the General Manager for Incyte Biosciences Canada, expanding the its North American…

April 3, 2020 Off

Novartis, Incyte test using Jakavi for respiratory problems in COVID-19 patients

By Dino Mustafić

Novartis said on Thursday it aims to start a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for the treatment of a type of severe immune overreaction called cytokine storm that can lead to life-threatening respiratory complications in patients with COVID-19.

September 25, 2019 Off

Incyte treats first vitiligo patient in phase 3 clinical trial of ruxolitinib cream

By BusinessWire

Incyte has treated first vitiligo patient in its phase 3 clinical trial testing ruxolitinib cream as a monotherapy for older patients older than 12.

July 2, 2019 Off

Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China

By BusinessWire

WILMINGTON, Del. & SHANGHAI–(BUSINESS WIRE)–$INCY–Incyte (NASDAQ:INCY) and Zai Lab Ltd. (NASDAQ:ZLAB) today announced that the companies have entered into a…

May 28, 2019 Off

FDA Approves Jakafi for the Treatment of Patients with Acute Graft-Versus-Host Disease

By BusinessWire

Jakafi is the first and only FDA-approved treatment for patients with
steroid-refractory acute graft-versus-host disease (GVHD)

April 30, 2019 Off

Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs

By BusinessWire

Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the…

March 15, 2019 Off

Company Profile for Incyte Corporation

By BusinessWire

–(BUSINESS WIRE)–Incyte is a global biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to meet serious…